A new study exposes challenges in reversing opioid overdoses with naloxone when potent synthetic drugs like fentanyl and ...
Osteoarthritis affects around 600 million people globally. It causes pain, stiffness, and reduced joint function—most commonly in the knees, hands, and hips.
The FDA approves Apotex Corp.'s plan to introduce generic Ozempic, a semaglutide injection that one study suggests could ...
ALMOST nine in ten slimmers on weight loss jabs fail to eat enough protein, risking hair loss and saggy skin, research ...
Weight loss injections which can be prescribed by the NHS are: semaglutide, marketed under the brand name Wegovy tirzepatide, sold as Mounjaro liraglutide, sold as Saxenda The drugs are given as ...
Eswatini, the country with the highest HIV prevalence in the world, is one of the first places to distribute lenacapavir, an ...
The US Food and Drug Administration announced on Thursday its approval of a new, higher-dose Wegovy (semaglutide) injection. The 7.2 mg dosage, called Wegovy HD, is intended for weight loss and ...
The U.S. Food and Drug Administration announced on Thursday its approval of a new, higher-dose Wegovy (semaglutide) injection. The 7.2 mg dosage, called Wegovy HD, is intended for weight loss and long ...
Three Indian firms launched generic semaglutide after patent expiry for diabetes and obesity treatment Sun Pharma markets Noveltreat and Sematrinity with weekly costs from Rs 750 to Rs 2,000 Zydus ...
Novo Nordisk's higher dosage Wegovy weight-loss medication was approved in the U.S., as the pharmaceutical giant faces looming competition in the sector. The Danish drugmaker said on Thursday its ...
The FDA has approved a new higher-dose version of injectable semaglutide (Wegovy HD, Novo Nordisk) for both weight loss and long-term weight-loss maintenance. The higher dose, 7.2 mg, produced an ...
A date has been set for the rollout of the redesigned Mounjaro KwikPens in the UK, killing off the controversial 'golden dose' once and for all. The change means some Mounjaro users will soon receive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results